- ￥5488
- MedChemExpress(MCE)
- 美国
- HY-16014
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
406228-55-5
- 规格：
10 mM * 1 mL///100 mg
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
A-385358
CAS No. : 406228-55-5
MCE 国际站：A-385358
产品活性：A-385358 是 Bcl-XL 的一个选择性抑制剂，对于 Bcl-XL 和 Bcl-2 的 Ki 值分别为 0.80 和 67 nM。
研究领域：Apoptosis
作用靶点：Bcl-2 Family
In Vitro: A-385358 is a selective inhibitor of Bcl-XL with Kis of 0.80 and 67 nM for Bcl-XL and Bcl-2, respectively, in fluorescence polarization assays. Treatment of IL-3-deprived FL5.12/Bcl-XL cells for 24 hours with A-385358 results in cell killing with an EC50 of 0.47±0.05 μM (n=68). This effect is accompanied by an increase in caspase-3 activity. Consistent with the greater affinity for the Bcl-XL versus Bcl-2 hydrophobic grooves, the EC50 of A-385358 for IL-3-depleted FL5.12/Bcl-2 cells (1.9±0.1 μM; n=55) is 4-fold higher relative to the cytokine-deprived FL5.12/Bcl-XL cells. In addition, A-385358 is more effective at stimulating cytochrome c release from mitochondria isolated from FL5.12/Bcl-XL versus Bcl-2 cells.
In Vivo: The combination of A-385358 given at 100 mg/kg/d plus the lower dose of paclitaxel produces a significant reduction in tumor growth (%T/C) compare with paclitaxel monotherapy. This combination also yields a >100% increase in time for tumors to reach 900 mm3 (%ILS) compare with vehicle control. Maximal efficacy is observed during the dosing period for A-385358, with slow but steady increase in the tumor growth after termination of treatment. The combination of A-385358 at 75 mg/kg/d plus paclitaxel at 30 mg/kg/d is also well tolerated and inhibits tumor growth rate by nearly 80%. Significant effects on tumor growth relative to paclitaxel monotherapy are observed with doses as low as 50 mg/kg/d.
相关产品：Bioactive Compound Library Plus | Apoptosis Compound Library | Anti-Cancer Compound Library | Peptidomimetic Library | Anti-Blood Cancer Compound Library | Mitochondria-Targeted Compound Library | Targeted Diversity Library | Highly Selective Inhibitors Library | Venetoclax | Navitoclax | Polyinosinic-polycytidylic acid | S63845 | ABT-737 | A-1331852 | AZD-5991 | BT2 | Chlorin e6 | A-1155463 | MIK665 | Estradiol benzoate | BAI1 | Benzbromarone | Obatoclax Mesylate | Digitoxin | Chelerythrine chloride | BI-3802 | AZD4320 | Dehydrocorydaline | WEHI-539 hydrochloride | Tapotoclax | Amantadine | A-1210477 | Gambogic Acid | BTSA1 | Bax inhibitor peptide V5 | UMI-77 | Cardamonin | TCPOBOP
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验μL 体系 2× MasterMix 25 μL 上游 Primer （ 10 μM 1-5 μL 下游 Primer （ 10 μM ） 1-5 μL 模板 lamid DNA ～ 50 ng genomic DNA ～ 1000 ng cDNA ～ 500 ng 粗提液 ～ 2 μL 灭菌蒸馏水至 50 μL PCR 扩增实例： 一、plasmid DNA 扩增 1．提取的质粒 DNA 扩增 以pUC19 质粒为模板扩增 100，250，500
DNA EXTRACTION FROM MICRODISSECTED PARAFFIN SECTIONS
diiferent blades for each part of the tumor. Overlay with 20 ul mineral oil. Close cap and seal with parafilm. DIGESTION: Incubate overnight for shaking at 120 rpm, 55 C. Day 2: Add 0.3 ul fresh conc Proteinase K (20 mg/ml stock
1. 生信分析文章范例解读 最近在检索文献时发现了 10 月有一篇生信文章，做的是关于三阴性乳腺癌中相关 ceRNA 差异表达谱的综合分析，于 2018 年 10 月 11 日发表在《Cellular physiology and biochemistry》杂志上，IF = 5.5。 由于小编就是做三阴性乳腺癌 non-coding RNA 的相关研究，一直都有关注 ceRNA 的研究，类似这篇文章的工作量投稿分数应为 3-5 分，而此文竟然突破 5 分门槛。 仔细阅读发现，原来这篇文章与常规
技术资料暂无技术资料 索取技术资料
